Bone Biologics Receives Approval for Trial of NB1 Growth Factor in Australia

Bone Biologics received Human Research Ethics Committee approval for the first center of a multicenter pilot clinical trial to evaluate NB1 recombinant human protein growth factor (NELL-1/DBX®) in 30 patients in Australia. The study will examine the treatment of one-level degenerative disc disease in patients who may also have up to Grade 1...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us